VentureMed, the company behind the FLEX Vessel Prep system for arteriovenous (AV) access and peripheral arterial disease (PAD) interventions, is now doing business as Flex Vascular.
“The DBA (Doing Business As) name reflects the company’s focused commitment to vascular innovation and aligns directly with its flagship technology, the FLEX Vessel Prep system,” the company announced in a press release.
“Flex Vascular more clearly represents who we are and what we do,” said Denis Harrington, the company’s CEO. “As adoption of FLEX Vessel Prep has grown, it became increasingly important that our public-facing name clearly align with our vascular focus and the technology we bring to clinicians and patients.”
VentureMed Group, Inc. remains the company’s legal corporate entity. “The transition to operating as Flex Vascular is a branding update and does not involve a change in ownership, leadership, corporate structure, product offerings or regulatory status,” the company press release added.
FLEX Vessel Prep is US Food and Drug Administration (FDA) 510(k)-cleared and CE mark-approved.
